Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THM401
- Development stage
- Phase 1
- Lead developer
- 成都四面体药物研究有限公司
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
THM401 is an investigational small molecule beta-lactamase inhibitor (BLI) developed by Chengdu Tetrahedron Drug Research for the treatment of serious infections caused by Gram-negative bacteria. It is primarily intended for use in combination with ceftazidime, a third-generation cephalosporin, to address resistance mediated by beta-lactamase production. The combination therapy is being evaluated for indications such as complicated urinary tract infections (cUTI) and pyelonephritis. THM401 is administered via intravenous injection. As of 2024, it is undergoing Phase I clinical trials in China to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers, both as a single agent and in combination with ceftazidime.
02
Targets
β-lactamase
Beyond the preview
Go deeper on THM401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THM401.